Drugs / HCB301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06487624 | Apr 2025 → Dec 2026 expected | Hodgkins lymphoma | FBD Biologics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | HanchorBio Inc. | Results HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301 hanchorbio.com ↗
HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea. |
| 2026-06-01 | HanchorBio Inc. | Results HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress hanchorbio.com ↗
HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. |
| 2026-04-03 | HanchorBio Inc. | Results HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path hanchorbio.com ↗
Early signals of activity were observed, with a disease control rate (DCR) of ~35.7% across dose levels, supporting the biological premise of integrating innate immune activation, adaptive checkpoint modulation, and tumor microenvironment remodeling within one molecule. |
| 2026-03-16 | HanchorBio Inc. | Results HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026 hanchorbio.com ↗
Initial Phase 1 dose-escalation results demonstrate manageable safety and support continued clinical evaluation of next-generation multi-checkpoint engineering. |
| 2025-11-06 | HanchorBio Inc. | Results HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ hanchorbio.com ↗
Novel fusion protein shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. |
| 2024-06-28 | HanchorBio Inc. | Regulatory HANCHORBIO ANNOUNCES US FDA CLEARANCE OF IND APPLICATION FOR HCB301 TRI-SPECIFIC FUSION PROTEIN TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES hanchorbio.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCB301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06487624 ↗ |
| Modality | Protein / enzyme biologic | “Tgf-β fusion protein” NCT06487624 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT06487624 ↗ |